These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
237 related articles for article (PubMed ID: 24603328)
41. Prognostic significance of HER2 expression in neuroblastic tumors. Izycka-Swieszewska E; Wozniak A; Kot J; Grajkowska W; Balcerska A; Perek D; Dembowska-Baginska B; Klepacka T; Drozynska E Mod Pathol; 2010 Sep; 23(9):1261-8. PubMed ID: 20581805 [TBL] [Abstract][Full Text] [Related]
42. HuC/D expression in small round cell tumors and neuroendocrine tumors: a useful tool for distinguishing neuroblastoma from childhood small round cell tumors. Takemoto J; Kuda M; Kohashi K; Yamada Y; Koga Y; Kinoshita I; Souzaki R; Taguchi T; Oda Y Hum Pathol; 2019 Mar; 85():162-167. PubMed ID: 30468801 [TBL] [Abstract][Full Text] [Related]
43. [Study on MYCN gene amplification and CD44 expression in neuroblastoma]. Hu HL; He LJ Zhonghua Bing Li Xue Za Zhi; 2004 Aug; 33(4):332-6. PubMed ID: 15363318 [TBL] [Abstract][Full Text] [Related]
44. [Molecular genetic abnormalities of N-myc and C-myc in pediatric neuroblastic tumors and clinical pathologic significance]. Cai RQ; Zhou CJ; Sun QN; Ma XL; Wang M; Li Y; Wang DY; Gong LP Zhonghua Bing Li Xue Za Zhi; 2013 May; 42(5):299-304. PubMed ID: 24004585 [TBL] [Abstract][Full Text] [Related]
45. The low-affinity neurotrophin receptor, p75, is upregulated in ganglioneuroblastoma/ganglioneuroma and reduces tumorigenicity of neuroblastoma cells in vivo. Schulte JH; Pentek F; Hartmann W; Schramm A; Friedrichs N; Øra I; Koster J; Versteeg R; Kirfel J; Buettner R; Eggert A Int J Cancer; 2009 May; 124(10):2488-94. PubMed ID: 19142969 [TBL] [Abstract][Full Text] [Related]
46. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma. Masserot C; Liu Q; Nguyen E; Gattolliat CH; Valteau-Couanet D; Bénard J; Huber C; Ségal-Bendirdjian E Mol Oncol; 2016 Feb; 10(2):240-52. PubMed ID: 26482175 [TBL] [Abstract][Full Text] [Related]
47. An ultrastructural and immunohistochemical evaluation of cytodifferentiation in neuroblastic tumors. Hachitanda Y; Tsuneyoshi M; Enjoji M Mod Pathol; 1989 Jan; 2(1):13-9. PubMed ID: 2922387 [TBL] [Abstract][Full Text] [Related]
48. Prognostic factors in neuroblastoma. Clinical, histopathologic, and immunohistochemical features and DNA ploidy in relation to prognosis. Oppedal BR; Storm-Mathisen I; Lie SO; Brandtzaeg P Cancer; 1988 Aug; 62(4):772-80. PubMed ID: 3395959 [TBL] [Abstract][Full Text] [Related]
49. Treatment and outcome of Ganglioneuroma and Ganglioneuroblastoma intermixed. Decarolis B; Simon T; Krug B; Leuschner I; Vokuhl C; Kaatsch P; von Schweinitz D; Klingebiel T; Mueller I; Schweigerer L; Berthold F; Hero B BMC Cancer; 2016 Jul; 16():542. PubMed ID: 27465021 [TBL] [Abstract][Full Text] [Related]
51. Tumors of the neuroblastoma group. Shimada H Pathology (Phila); 1993; 2(1):43-59. PubMed ID: 9420930 [TBL] [Abstract][Full Text] [Related]
52. IGF2BP1 harbors prognostic significance by gene gain and diverse expression in neuroblastoma. Bell JL; Turlapati R; Liu T; Schulte JH; Hüttelmaier S J Clin Oncol; 2015 Apr; 33(11):1285-93. PubMed ID: 25753434 [TBL] [Abstract][Full Text] [Related]
54. Galectin-3 expression is prognostic in diffuse type gastric adenocarcinoma, confers aggressive phenotype, and can be targeted by YAP1/BET inhibitors. Ajani JA; Estrella JS; Chen Q; Correa AM; Ma L; Scott AW; Jin J; Liu B; Xie M; Sudo K; Shiozaki H; Badgwell B; Weston B; Lee JH; Bhutani MS; Onodera H; Suzuki K; Suzuki A; Ding S; Hofstetter WL; Johnson RL; Bresalier RS; Song S Br J Cancer; 2018 Jan; 118(1):52-61. PubMed ID: 29136404 [TBL] [Abstract][Full Text] [Related]
55. Discrimination of histopathologic types of childhood peripheral neuroblastic tumors based on clinical and biological factors. Yang S; Cai S; Ma X; Zeng Q; Qin H; Han W; Peng X; Wang H Sci Rep; 2018 Jul; 8(1):10924. PubMed ID: 30026516 [TBL] [Abstract][Full Text] [Related]
57. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification. Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322 [TBL] [Abstract][Full Text] [Related]
58. Single-cell profiling of peripheral neuroblastic tumors identifies an aggressive transitional state that bridges an adrenergic-mesenchymal trajectory. Yuan X; Seneviratne JA; Du S; Xu Y; Chen Y; Jin Q; Jin X; Balachandran A; Huang S; Xu Y; Zhai Y; Lu L; Tang M; Dong Y; Cheung BB; Marshall GM; Shi W; Carter DR; Zhang C Cell Rep; 2022 Oct; 41(1):111455. PubMed ID: 36198269 [TBL] [Abstract][Full Text] [Related]